Esmolol + Metoprolol

ApprovedTerminated
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Vascular Disease

Conditions

Vascular Disease, Hypertension, Angina, Cardiac Disease

Trial Timeline

Apr 1, 2011 โ†’ Dec 1, 2013

About Esmolol + Metoprolol

Esmolol + Metoprolol is a approved stage product being developed by Baxter for Vascular Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01404767. Target conditions include Vascular Disease, Hypertension, Angina.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01404767ApprovedTerminated

Competing Products

20 competing products in Vascular Disease

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
33
CLS-AX + AfliberceptClearside BiomedicalPhase 2
44
Eylea + ALT-L9AlteogenPhase 1
33
Dulaglutide + PlaceboEli LillyPhase 3
77
raloxifene + placeboEli LillyPhase 3
77
EvacetrapibEli LillyPhase 1
33
Orforglipron + PlaceboEli LillyPhase 3
77
UBX1325 injection 50 ฮผL + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
44
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
52
Rosuvamibe + MonorovaYuhanApproved
85
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
85
Rosuvamibe + MonorovaYuhanApproved
85
olmesartanDaiichi SankyoPre-clinical
23
DS-7080a + RanibizumabDaiichi SankyoPhase 1
33
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
85
Avacincaptad PegolAstellas PharmaPhase 1
33
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
52
LexiscanAstellas PharmaPhase 2
52
YM872 (zonampanel)Astellas PharmaPhase 2
52
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
52